Insight

Rod Carlo Columbres: Allosteric inhibition of human p97/VCP ATPase by triazole inhibitors

Photo taken from Rod Carlo Columbres/X

Aug 12, 2024, 19:57

Rod Carlo Columbres: Allosteric inhibition of human p97/VCP ATPase by triazole inhibitors

Rod Carlo Columbres, Research Fellow at , on X:

“Happy to share our new publication.

Mechanism of allosteric inhibition of human p97/VCP ATPase and its disease mutant by triazole inhibitors.

Glad all the hard work I put in while California Institute of Technology is still in fruition!”

Mechanism of allosteric inhibition of human p97/VCP ATPase and its disease mutant by triazole inhibitors

Autors: Purbasha Nandi, Kira DeVore, Feng Wang, Shan Li, Joel D. Walker, Thanh Tung Truong, Matthew G. LaPorte, Peter Wipf, Heidi Schlager, John McCleerey, William Paquette, Rod Carlo A. Columbres, Taiping Gan, Yu-Ping Poh, Petra Fromme, Andrew J. Flint, Mark Wolf, Donna M. Huryn, Tsui-Fen Chou and Po-Lin Chiu

Allosteric

Source: Rod Carlo Columbres/X

Andrew J. Flint California Institute of Technology cancer Donna M. Huryn Feng Wang Heidi Schlager Joel D. Walker John McCleerey Kira DeVore Mark Wolf Matthew G. LaPorte OncoDaily Oncology Peter Wipf Petra Fromme Po-Lin Chiu Purbasha Nandi Rod Carlo A. Columbres Rod Carlo Columbres Shan Li Taiping Gan Thanh Tung Truong Tsui-Fen Chou William Paquette Yu-Ping Poh

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage